Toxic metabolic products resulting from halothane biotransformation are thought to be a possible mechanism of halothane hepatotoxicity [1, 2] . Metabolism of halothane occurs in man via both oxidative and reductive pathways. Van Dyke has demonstrated that metabolism takes place in liver microsomes [3] ; cimetidine has been reported to bind to liver microsomal enzymes, specifically cytochromes P450 and P448 [4] . Consequently, cimetidine can impair the metabolism of drugs that are metabolized by the mixed-function oxidase enzyme system. Drugs known to be affected in man in this way include anticoagulants, benzodiazepines, beta blockers, theophylline, anticonvulsants [5] and lignocaine [6] . Animal experiments suggest that cimetidine reduces halothane metabolism and consequently lessens the severity of hepatic injury. Although two groups of workers have demonstrated this reduction, they differed on whether or not it is the oxidative or reductive pathway of metabolism that is inhibited [7, 8] .
Glutathione S-transferase B 1 B 1 (GST) concentration in plasma is known to provide a more sensitive index of drug-induced hepatocellular damage [9] and correlates better with hepatic histology than the serum transaminase concentrations [10] . We have demonstrated previously that halothane anaesthesia produced significant increase in plasma GST concentration 3 h after anaesthesia. In some patients a larger secondary increase in GST occurred 24 h after anaesthesia. It has been suggested that the peak in GST occurring at 3 h results from alterations in hepatic blood flow whilst the increase at 24 h may be caused by production of toxic metabolites [11] . Correspondence to D.C.R. We have assessed the possibility that administration of cimetidine before anaesthesia could prevent the release of GST following halothane anaesthesia in man.
SUMMARY

PATIENTS AND METHODS
The study was approved by the Area Ethics Committee. Informed consent was obtained from patients aged 16-70 yr (ASA class I or II) undergoing minor orthopaedic surgery such as arthroscopy. Patients receiving regular oral medication of any type and those who had undergone halothane anaesthesia in the preceding 3 months were not included. Obesity (weight > 120% expected), excessive alcohol consumption (> 3 units day" 1 ) and a history of previous liver disease or recent blood transfusion also resulted in exclu-sion. Patients were excluded from analysis if their duration of anaesthesia exceeded 90 min. Patients were assigned randomly to one of two groups, to receive cimetidine 800 mg orally the evening before operation with a further 800 mg given at the time of premedication, or equivalent placebo tablets.
Premedication comprised oral temazepam 20 mg 1 h before operation. Anaesthesia was induced with thiopentone 4-6 mg kg" 1 i.v. and was maintained with 66% nitrous oxide and halothane in oxygen. All patients breathed spontaneously via a Lack Mk II system with a fresh gas flow rate of 6 litre min"
1 . End-tidal concentrations of halothane (Penlon Halothane meter) and carbon dioxide (Hewlett-Packard 47210A capnometer) were recorded every 5 min for the duration of anaesthesia. Patients were withdrawn if the end-tidal carbon dioxide exceeded 8 kPa. The mean of these endtidal concentrations was determined for each patient and a time-weighted halothane average calculated (mean end-tidal halothane concentration x duration of anaesthesia in minutes).
Blood samples were taken for GST assay before operation and at 3, 6 and 24 h after induction of anaesthesia. Measurements of conventional liver function tests were made on the day before and the day after anaesthesia.
Concentrations of bilirubin, alanine aminotransferase (ALT) and gamma glutamyl transferase (GGT) were measured using a Sequential Multiple Analysis with Computer System II (SMAC) (Technicon Instrument Corporation, Basingstoke, U.K.). Plasma basic GST concentration (Bj subunits) was measured by specific radioimmunoasay [12] , with a reference range for GST of 0.7-4.0 ug litre" 1 . The interassay coefficient of variation was less than 10%, and the intra-assay coefficient of variation was less than 5 % over the range 0.2-40 ug litre" 1 .
Statistical analysis
The demographic data and anaesthetic characteristics for each group were compared using Student's t test. Changes in GST concentrations within each group were compared using the Friedman test. The GST changes from the preoperative values at 3,6 and 24 h after induction of anaesthesia were compared using the Wilcoxon signed rank test. Differences in GST changes at these times between the two groups and postoperative conventional liver function tests relative to preoperative values were compared using the Wilcoxon rank sum test. Correlation of GST changes with total dose of halothane adminstered, and with mean end-tidal carbon dioxide concentration was with Spearman's rank coefficient [13] . A four-fold table Chi squared test was used to compare the incidence of abnormal GST values in each group.
RESULTS
Fifty-three patients were studied: 26 received placebo (16 male, 10 female) and 27 cimetidine (18 male, 9 female). Eight patients were subsequently excluded from analysis: three were withdrawn because of excessive duration of anaesthesia (> 90 min), three had abnormal preoperative liver function tests, one refused to have further blood samples taken and surgery was cancelled in one. End-tidal carbon dioxide did not exceed 8 kPa in any patient. Data from the remaining 45 patients were analysed: 24 had received placebo (14 male, 10 female) and 21 cimetidine (14 male, 7 female).
The groups were comparable in age, height, weight, % expected weight and alcohol intake (table I). The mean dose of thiopentone and the mean end-tidal concentrations of halothane and carbon dioxide were similar in the two groups. The total dose of halothane administered, reflected in the time-weighted halothane average, appeared greater in the placebo group, despite the random allocation design of the study, but this failed to achieve statistical significance. Twentytwo patients in the placebo group and 17 in the cimetidine group had received previous anaesthesia. Significant changes occurred in postoperative plasma concentrations of GST in both groups (P < 0.001 both groups). GST increased significantly 3 h after induction in both groups, and at 6 h in the group receiving cimetidine (table II) .
Some patients in each group showed an increase in GST concentration which exceeded the upper limit of the reference range (4.0 ug litre" 1 ) ( fig. 1 ). There was no significant difference in the frequency of such abnormal values between the two groups. One patient in the placebo group exhibited a large secondary increase in GST at 24 h, but no patient receiving cimetidine showed a comparable change. Cimetidine did not appear to influence the magnitude of increase in GST at 3 and 6 h. There was no correlation between GST increase and total dose of halothane administered, or mean end-tidal carbon dioxide concentration. Concentrations of bilirubin, ALT and GGT were not significantly different relative to preoperative values in each group (table III) . DISCUSSION GST has been shown previously to be released following anaesthesia with halothane and enflurane but not isoflurane [14, 15] . The present study has been unable to demonstrate that cimetidine influenced GST release at 3 and 24 h following halothane anaesthesia. Although no patient receiving cimetidine exhibited a large secondary increase in GST concentration at 24 h, it would be necessary to study many more patients to be certain that cimetidine prevented this less frequent increase.
Halothane biotransformation occurs in vitro [16] and in vivo [17] and this takes place in the 16 16 Post.
16 15 15 Pre. 14 20 22 Post. microsomal fraction of the liver [3] . The binding of halothane metabolites to rat liver microsomes is enhanced by agents that induce cytochrome P450, such as phenobarbitone [3] , and reduced by enzyme inhibitors such as SKF-525-A [18] . In rats exposed to halothane, Jee and colleagues demonstrated increased hepatotoxicity after induction of cytochrome P450 and showed that significant protection was afforded by pretreatment with enzyme inhibitors [19] . More recently, cimetidine has been shown to offer protection against halothane hepatotoxicity in rats [7, 8] , although the reports differ on the identity of the pathway of metabolism inhibited. In hypoxic rats, Plummer and others [7] suggested that cimetidine reduced reductive metabolism. In contrast, Wood and co-workers [8] showed that cimetidine reduced oxidative metabolism of halothane in normal untreated rats, but failed to demonstrate that cimetidine reduced metabolism by these two pathways in the hypoxia/enzyme-induced or triiodothyronine models.
Possible reasons for the differences in the observations of the influences of cimetidine on metabolism in animals and the negative result of this study in man include other potential effects of cimetidine such as those on hepatic blood flow, and perhaps inadequate dosage of cimetidine.
Original evidence suggested that cimetidine reduced hepatic blood flow. Such a reduction in flow and resultant ischaemia could contribute to the release of GST. Feely and colleagues [20] used clearance of indocyanine green as a measure of hepatic blood flow, to demonstrate a reduction after administration of cimetidine. The limitations of this technique have been stressed by Groszmann, who suggested that the extraction ratio should be measured when utilizing clearance techniques [21] . This was not performed in Feely's study. Further investigation has failed to demonstrate a reduction in liver blood flow by cimetidine using various techniques, such as clearance of galactose [22] and more direct methods including the use of an electromagnetic blood flow meter [23] , an ultrasound Doppler system or cineangiography [24] . Thus there is no convincing evidence that cimetidine has any effect on hepatic blood flow. If the increase in GST concentration at 3 h results from changes in liver blood flow caused by halothane, data from the present study suggest that cimetidine causes no additional alteration in hepatic perfusion.
The doses of cimetidine given in the rat studies were enormous (120 and ISOmgkg" 1 ) and it is obviously not possible to administer such large doses to man. Most human studies which have shown that cimetidine impairs metabolism of other drugs have involved giving a larger total dose of cimetidine than that given in this study. This usually involved pretreatment with cimetidine for 2-14 days [25] [26] [27] . Klotz and co-workers have shown that a single oral dose of cimetidine 800 mg is sufficient to interfere with the pharmacokinetics of midazolam administered concurrently [28] . This single dose also achieved plasma concentrations of cimetidine within the therapeutic range as evaluated by Somogyi [29] . However, when cimetidine was given in a total dose of 600 mg to patients undergoing enflurane anaesthesia, the metabolism of enflurane was not altered significantly as assessed by serum fluoride concentrations [30] .
If it can be assumed that the dose of cimetidine used was sufficient to reduce halothane metabolism, our data suggest that products of halothane metabolism are not responsible for the early release of GST described previously [11, 14, 15] . Several other theories should be investigated before the true nature of liver dysfunction associated with halothane (as indicated by GST release) is fully understood.
